MediWound Announces Collaboration With MIMEDX On EscharEx Phase III Study
Portfolio Pulse from Happy Mohamed
MediWound Ltd. (NASDAQ:MDWD) has entered into a research collaboration agreement with MIMEDX Group, Inc (NASDAQ:MDXG) for the EscharEx Phase III study in venous leg ulcers (VLUs). MIMEDX will provide its placental tissue allograft EPIFIX to be used during the wound healing phase of the study. The aim is to maintain consistency among study subjects and optimize the potential for complete healing throughout the study duration.
August 15, 2023 | 8:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MediWound's collaboration with MIMEDX for the EscharEx Phase III study could potentially enhance the company's product portfolio and reputation in the biopharmaceutical industry.
The collaboration with MIMEDX allows MediWound to incorporate a market-leading allograft in its study, which could potentially enhance the study's outcomes and the company's reputation in the industry.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
MIMEDX's collaboration with MediWound for the EscharEx Phase III study could potentially increase the usage and recognition of its product EPIFIX in the biopharmaceutical industry.
The collaboration with MediWound allows MIMEDX's EPIFIX to be used in a significant study, which could potentially increase its usage and recognition in the industry.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100